The government is now operating in accordance with the Guidance on Caretaker Conventions, pending the outcome of the 2025 federal election.
TAVNEOS (Vifor Pharma Pty Ltd)
Product name
TAVNEOS
Sponsor
Date registered
Evaluation commenced
Decision date
Approval time
202 (255 working days)
Active ingredients
avacopan
Registration type
NCE/NBE
Indication
Tavneos, in combination with a rituximab or cyclophosphamide based regimen, is indicated for the treatment of adults with anti-neutrophil cytoplasmic autoantibody (ANCA)-associated vasculitis (granulomatosis with polyangiitis [GPA] and microscopic polyangiitis [MPA]).